Vantage logo

Unpacking Royalty Pharma

The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.

Vantage logo

Biotech catalysts on the horizon

The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.